Abstract
Adriamycin and cyclophosphamide are active agents in human and experimental tumours. Using the L1210 murine leukaemia, their effectiveness alone and in combination was studied. The combination is highly synergistic in this tumour, resulting in a greater than 50% survival rate when the agents used alone at optimal doses are not curative. DNA synthesis by tumour cells is substantially inhibited and the total ascitic population much reduced. In contrast, DNA synthesis in sensitive host tissues is less disturbed. There is no major difference in the pharmacology of the agents whether given alone or in combination. In very advanced disease the combination is no better than treatment with cyclophosphamide alone. The combination of adriamycin and melphalan in L1210 leukaemia also produces superior results to those obtained using either drug alone at its optimal dosage.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahmann D. L., Bisel H. F., Eagan R. T., Edmonson J. H., Hahn R. G. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep. 1974 Nov-Dec;58(6):877–882. [PubMed] [Google Scholar]
- BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Blum R. H., Carter S. K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med. 1974 Feb;80(2):249–259. doi: 10.7326/0003-4819-80-2-249. [DOI] [PubMed] [Google Scholar]
- Bonadonna G., Monfardini S., De Lena M., Fossati-Bellani F., Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res. 1970 Oct;30(10):2572–2582. [PubMed] [Google Scholar]
- Corbett T. H., Griswold D. P., Mayo J. G., Laster W. R., Schabel F. M., Jr Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res. 1975 Jun;35(6):1568–1573. [PubMed] [Google Scholar]
- Fisher B., Carbone P., Economou S. G., Frelick R., Glass A., Lerner H., Redmond C., Zelen M., Band P., Katrych D. L. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975 Jan 16;292(3):117–122. doi: 10.1056/NEJM197501162920301. [DOI] [PubMed] [Google Scholar]
- Muggia F. M., Perloff M., Chia G. A., Reed L. J., Escher G. C. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation. Cancer Chemother Rep. 1974 Nov-Dec;58(6):919–926. [PubMed] [Google Scholar]
- Sandberg J. S., Howsden F. L., DiMarco A., Goldin A. Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Cancer Chemother Rep. 1970 Feb;54(1):1–7. [PubMed] [Google Scholar]